[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600666":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":49,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Southeast University, China","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients With Myocardial Ischemia-Reperfusion Injury",null,[12],"Diagnostic Test: Blood Biomarker Profiling and Prognostic Follow-up",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Blood Biomarker Profiling and Prognostic Follow-up","Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry\u002FELISA\u002Fflow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Wenbin Lu, PhD","CONTACT","+86 13605185175","101012092@seu.edu.cn",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Yahao Zhang, M.D.","+86 13523060936","zhyh626@163.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Cardiology, Zhongda Hospital, Southeast University","RECRUITING","Nanjing","Jiangsu","210009","China","CN",{"type":39,"coordinates":40},"Point",[41,42],118.77778,32.06167,{"lat":42,"lon":41},[45],{"name":46,"role":22,"phone":47,"phoneExt":10,"email":48},"Tingting Xiao, M.D.","+86 16605198956","230249327@seu.edu.cn",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Genshan Ma","Director of Cardiovascular Medicine & Deputy Director of Cardiovascular Disease Research Institute, Zhongda Hospital Southeast University; Professor (Level-II); Chief Physician; PhD Advisor; Chairman, Cardiovascular Society of Jiangsu Medical Association","100600666","or6a2-on-monocytes-and-cardiovascular-outcomes-in-myocardial-ischemia-reperfusion-injury-100600666",false,"NCT07100457","OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury","Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury","Inclusion Criteria:\n\n1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.\n2. Age 18-90 years inclusive.\n\nExclusion Criteria:\n\n1. Active systemic infections.\n2. Advanced heart failure (NYHA class III-IV).\n3. Acute cerebrovascular conditions.\n4. Active myocarditis.\n5. cardiomyopathy.\n6. Refractory ventricular tachycardia\u002Ffibrillation.\n7. Diagnosis\u002Fconcurrent treatment for malignancy within 5 years (except non-melanoma skin cancer\u002Fcarcinoma in situ).\n8. Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73m2 or dialysis dependence).\n9. Child-Pugh class C hepatic dysfunction.","ALL","18 Years","90 Years",{"count":64,"type":65},200,"ESTIMATED","44 Months","OBSERVATIONAL","This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress\u002Finflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2\u002Foctanal\u002Finflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.",[70],"Myocardial Ischemia-Reperfusion Injury","2025-07-30",{"date":73,"type":74},"2025-08-03","ACTUAL",{"date":76,"type":74},"2019-09-01",{"date":78,"type":65},"2027-08-30",{"name":5,"class":6},1]